|
24 Companies |
|
9 Products |
|
9 Products |
|
6 Mechanisms of Action |
|
50 Trials |
|
3648 News |
|
| «12...48495051525354555657585960 |
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: SODA: Somatuline (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=200, Recruiting, Sponsor: Ipsen
N=160 --> 200
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=54, Completed, Sponsor: Ipsen
N=160 --> 200 Enrolling by invitation --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P4 trial, Surgery: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) - May 22, 2013
P4, N=24, Recruiting, Sponsor: John Wayne Cancer Institute
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment open: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Apr 24, 2013
P=N/A, N=152, Recruiting, Sponsor: Ipsen
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Non Interventional Post Marketing Programme in Acromegaly (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=42, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Signifor LAR (pasireotide long acting release) / Recordati
New P4 trial: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Feb 18, 2013
P4, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
- Trial completion: Peripheral Metabolic Effects of Somatostatin (clinicaltrials.gov) - Jan 17, 2013
P=N/A, N=8, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly (clinicaltrials.gov) - Jan 14, 2013
P3, N=533, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=360 --> 533
- ||| Enrollment open, HEOR: Acromegaly Treatment Quality of Life Study (clinicaltrials.gov) - Jan 13, 2013
P=N/A, N=120, Recruiting, Sponsor: Massachusetts General Hospital
N=360 --> 533 Not yet recruiting --> Recruiting
- Trial initiation date: Epidemiology of Acromegaly in Denmark 1991-2010 (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=500, Recruiting, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Feb 2013
- | Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (clinicaltrials.gov) - Dec 6, 2012
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2012 --> Feb 2013 Not yet recruiting --> Recruiting
- | atesidorsen (ATL1103) / Antisense Therap, Ionis
New P2 trial: A trial to assess whether the new drug ATL1103 is safe and effective in patients who have acromegaly (EUDRACT) - Nov 13, 2012
P2, N=30, Ongoing, Sponsor: Antisense Therapeutics Ltd
- | Signifor LAR (pasireotide long acting release) / Recordati
New P2 trial: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (clinicaltrials.gov) - Aug 26, 2012
P2, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
- octreotide implant (VP-003) / Endo
Trial termination: Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly (clinicaltrials.gov) - Aug 15, 2012
P3, N=12, Terminated, Sponsor: Endo Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Program was terminated for business reasons
- | octreotide acetate / Generic mfg.
Enrollment closed: Effects of Sandostatin LAR (clinicaltrials.gov) - Aug 7, 2012
P4, N=20, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Terminated; Program was terminated for business reasons Recruiting --> Active, not recruiting
- |||| Biomarker, Trial completion, Surgery: ESPORA: Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery (clinicaltrials.gov) - Jul 29, 2012
P4, N=55, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=25, Completed, Sponsor: Barts & The London NHS Trust
Recruiting --> Completed N=60 --> 25
- Trial completion: Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=25, Completed, Sponsor: Barts & The London NHS Trust
N=60 --> 25 Recruiting --> Completed
- | octreotide acetate / Generic mfg.
New P4 trial: Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target (clinicaltrials.gov) - Jun 11, 2012
P4, N=75, Recruiting, Sponsor: University of Aarhus
- Clinical: Prospective Study on Changes in Acromegaly (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=60, Recruiting, Sponsor: Radboud University
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SODA: Somatuline (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=200, Recruiting, Sponsor: Ipsen
Recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment change: Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=75, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Recruiting N=96 --> 75
- octreotide acetate solution for injection / Generic mfg.
Trial termination: Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas (clinicaltrials.gov) - Apr 23, 2012
P4, N=50, Terminated, Sponsor: Novartis Pharmaceuticals
N=96 --> 75 Completed --> Terminated
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: PRIMARYS: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (clinicaltrials.gov) - Feb 29, 2012
P3, N=108, Completed, Sponsor: Ipsen
Completed --> Terminated Active, not recruiting --> Completed
- Trial completion: Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency (clinicaltrials.gov) - Feb 6, 2012
P=N/A, N=75, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Somavert (pegvisomant) / Pfizer
Enrollment change, HEOR: Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=18, Completed, Sponsor: University of Aarhus
Recruiting --> Completed N=30 --> 18
- Somavert (pegvisomant) / Pfizer
Trial completion, HEOR: Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=18, Completed, Sponsor: University of Aarhus
N=30 --> 18 Active, not recruiting --> Completed
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: PRIMARYS: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (clinicaltrials.gov) - Nov 28, 2011
P3, N=108, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed N=90 --> 108
- |||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: POTA: Preoperative Octreotide Treatment of Acromegaly (clinicaltrials.gov) - Oct 19, 2011
P4, N=62, Completed, Sponsor: St. Olavs Hospital
N=90 --> 108 Active, not recruiting --> Completed
- | octreotide acetate / Generic mfg.
New P4 trial: Effects of Sandostatin LAR (clinicaltrials.gov) - Aug 24, 2011
P4, N=20, Active, not recruiting, Sponsor: Columbia University
- || Mycapssa (octreotide) / Chiesi
New P3 trial: Efficacy and Safety of Octreotide (MYCAPSSA (clinicaltrials.gov) - Aug 7, 2011
P3, N=150, Active, not recruiting, Sponsor: Chiasma, Inc.